What is behind programmatic treatment outcome definitions for tuberculosis?
Zaza Avaliani(National Center for Tuberculosis and Lung Disease), Askar Yedilbayev(World Health Organization Regional Office for Europe), I. А. Vаsilyevа(Pirogov Russian National Research Medical University), Martin van den Boom(World Health Organization Regional Office for the Eastern Mediterranean), Giorgi Kuchukhidze(World Health Organization Regional Office for Europe), Viorel Soltan, Alena Skrahina(Republican Scientific and Practical Centre of Pulmonology and Tuberculosis), Ogtay Gozalov(World Health Organization Regional Office for Europe), Valentina Vilc(Phthisiopneumology Institute "Chiril Draganiuc")
Cited by 14
Related Papers
Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study
|The Lancet Infectious Diseases|2017|688
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
|European Respiratory Journal|2019|176
The TB Portals: an Open-Access, Web-Based Platform for Global Drug-Resistant-Tuberculosis Data Sharing and Analysis
|Journal of Clinical Microbiology|2017|140
Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe
|European Respiratory Journal|2019|130